Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20187349 | 0.73 | DDB1 (0.44) | DDB1CRBNHCRTR2 | |
| SCHEMBL175365 | 0.73 | DDB1 (0.44) | DDB1CRBNHCRTR2 | |
| SCHEMBL3857278 | 0.72 | — | — | |
| SCHEMBL21643790 | 0.72 | HCAR2 (0.33) | — | |
| SCHEMBL15606537 | 0.63 | MGLL (0.49) | DDB1CRBNHCRTR2MGLLKMT2A | |
| SCHEMBL20292039 | 0.63 | DDB1 (0.46) | DDB1CRBNHCRTR2MGLLKMT2A | |
| SCHEMBL25816397 | 0.63 | DDB1 (0.43) | DDB1CRBNHCRTR2MGLLKMT2A | |
| SCHEMBL6440631 | 0.62 | — | — | |
| SCHEMBL15522347 | 0.62 | DDB1 (0.45) | DDB1CRBNHCRTR2MGLLKMT2A | |
| SCHEMBL24005500 | 0.62 | HTR2C (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605166-B2 | Synergistic mixture of methotrexate and integrin antigen or antibody | ELAN PHARMACEUTICALS INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-7320960-B2 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7229970-B2 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20050222119-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | WYETH | 2005-10-06 | — | — | US | disclosed |
| US-20050074451-A1 | Methods and compositions for treating rheumatoid arthritis | ELAN PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| US-20050065192-A1 | Methods and compositions for treating rheumatoid arthritis | ELAN PHARMACEUTICALS, INC. (US) | 2005-03-24 | — | — | US | disclosed |
| US-6525026-B2 | Antiinflammatory agents; cardiovascular disorders; rheumatic diseases | ELAN PHARMACEUTICALS, INC. | 2003-02-25 | — | — | US | disclosed |
| US-6489300-B1 | INHIBITORS OF ADHESION IN THE TREATMENT OF INFLAMMATORY BRAIN DISEASES AND OTHER INFLAMMATORY CONDITIONS | ELAN PHARMACEUTICALS, INC. | 2002-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222119-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, L1CAM | DDB1 2945/4885CRBN 973/4885HCRTR2 2306/4885 |
| US-20050065192-A1 | Methods and compositions for treating rheumatoid arthritis | VCAM1, ICAM1, ITGA4 | DDB1 2763/4885CRBN 1276/4885HCRTR2 4737/4885 |
| US-20050074451-A1 | Methods and compositions for treating rheumatoid arthritis | VCAM1, ICAM1, ITGA4 | DDB1 2763/4885CRBN 1276/4885HCRTR2 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.